Insmed (INSM) Amortizatization of Intangibles (2013 - 2026)
Insmed (INSM) recorded quarterly Amortizatization of Intangibles of $678000.0 in Q1 2026, down 65.0% quarter-over-quarter from $1.9 million in Q4 2025, and down 46.32% on a YoY basis from $1.3 million in Q1 2025.
Insmed (INSM) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Insmed's Amortizatization of Intangibles history runs 13 years deep, the most recent figure standing at $678000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 46.32% year-over-year to $678000.0; the TTM figure through Mar 2026 stood at $5.4 million (up 21.24% YoY), while the FY2025 annual figure was $6.0 million, up 121.28% from the prior year.
- Amortizatization of Intangibles was $678000.0 for Q1 2026 at Insmed, down from $1.9 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.9 million in Q4 2025 to a low of -$1.1 million in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $1.0 million across 5 years, with a median of $1.3 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles plunged 185.21% in 2023, then jumped 185.69% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $1.3 million in 2022, then slumped by 185.21% to -$1.1 million in 2023, then soared by 162.95% to $678000.0 in 2024, then surged by 185.69% to $1.9 million in 2025, then tumbled by 65.0% to $678000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $678000.0 (Q1 2026), $1.9 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 678,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 678,000.00 |
| Mar 31, 2026 | 678,000.00 |
| Dec 31, 2025 | 1.94 Mn |
| Dec 31, 2025 | 1.94 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 678,000.00 |
| Dec 31, 2024 | 678,000.00 |
| Sep 30, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 678,000.00 |
| Mar 31, 2024 | 678,000.00 |
| Dec 31, 2023 | -1.08 Mn |
| Dec 31, 2023 | -1.08 Mn |